The viral vector and plasmid DNA manufacturing market continues to experience rapid innovation and expansion, driven by advances in biotechnology and increasing demand for efficient, high-quality solutions. Recent milestones in this sector highlight the achievements of key players in enhancing production capabilities and service delivery.
The global viral vector and plasmid DNA manufacturing market size was estimated at US$ 6.01 billion in 2023 and is projected to grow to US$ 43.04 billion by 2034, rising at a compound annual growth rate (CAGR) of 20.7% from 2024 to 2034. This impressive growth is fueled by the evolving usage of plasmids and vectors across various applications, reflecting their critical role in advancing biopharmaceutical and gene therapy solutions.
Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5199
In July 2024, Kaneka Eurogentec, an FDA-inspected contract development and manufacturing organization (CDMO) specializing in injectable-grade cGMP biopharmaceuticals, achieved a significant breakthrough. The company successfully produced one kilogram of plasmid DNA in a single fermentation run for a leading drug development firm. This achievement demonstrates the efficiency and scalability of Kaneka Eurogentec’s production capabilities, setting a benchmark for high-yield plasmid DNA manufacturing. The milestone reflects the company’s commitment to advancing biopharmaceutical production to meet the growing needs of the industry.
In June 2024, GenScript Biotech Corporation announced the launch of the GenScript FLASH Gene service, a revolutionary sequence-to-plasmid (S2P) service. Known for its relentless innovation in synthetic biology, GenScript has introduced this flagship product to address the urgent demand for gene constructions with unparalleled speed, quality, and affordability. The GenScript FLASH Gene service represents a significant step forward in synthetic biology, enabling researchers to obtain high-quality gene constructs faster and more efficiently than ever before. This innovation underscores GenScript’s leadership in delivering cutting-edge solutions for gene synthesis.
In March 2024, Charles River Laboratories International, Inc. unveiled its Modular and Fast Track viral vector technology transfer frameworks. These frameworks, developed from decades of experience as a viral vector CDMO, are designed to streamline process transfers to its viral vector center of excellence (CoE) in Maryland. With this methodical approach, Charles River Laboratories can complete tech transfers in as little as nine months, ensuring faster and more efficient production timelines. The availability of these frameworks for download further emphasizes the company’s dedication to simplifying and accelerating viral vector manufacturing processes.
These developments highlight the transformative progress in the viral vector and plasmid DNA manufacturing market. Companies like Kaneka Eurogentec, GenScript Biotech Corporation, and Charles River Laboratories are leading the way in addressing industry challenges, from scaling up production to enhancing service speed and efficiency. Coupled with the market’s robust growth trajectory, these innovations play a crucial role in shaping the future of healthcare and biotechnology.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/viral-vector-and-plasmid-dna-manufacturing-market-sizing
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5199
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The AI in cancer drugs market is on a remarkable growth path, poised to generate substantial revenue between 2025 and… Read More
The global biostimulants market is on a steady rise. Valued at USD 3.06 billion in 2024, it's expected to grow… Read More
The dental insurance market is booming. In 2024, it was valued at $232.07 billion, grew to $253.72 billion in 2025,… Read More
The global market for bipolar disorder treatments was valued at USD 9.74 billion in 2025 and is projected to grow… Read More
The global polio vaccine market is growing steadily and is expected to rise from USD 904.57 million in 2025 to… Read More
The global market for specialty medical chairs is on the rise. Valued at USD 5.12 billion in 2025, it's projected… Read More